TX-MAVENIR
16.4.2024 13:01:29 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that the Mavenir Digital Enablement (MDE) is now available on Amazon Web Services (AWS) Marketplace.
Mavenir’s Digital Enablement (MDE) Business Support System (BSS) stack with composable architecture allows Communication Service Providers (CSPs) to implement innovative strategies and new selling models quickly, cost-effectively and with minimal risk, with the ability to test models iteratively and speed time-to-market without increasing capital and resource costs. MDE’s comprehensive set of modules already run on AWS – for reduced application-to-infrastructure test times – and span customer management, product catalog, order management, CRM, billing, converged charging, API monetization and network slice charging. With low-code/no-code visual builders and templated solutions-in-a-box, MDE is now available as a one-stop destination and digital marketplace for CSPs looking to implement new or complex models simply and agilely.
MDE offers a low-risk route to introducing profitable new business models such as split or sponsored billing, new package product offerings incorporating third-party solutions, automation for inter-partner manual tasks such as catalog mapping, and notifications mapping for service delivery to improve operational efficiency and the customer experience.
Mavenir’s Digital BSS has achieved platinum certification from TM Forum, with open APIs ensuring seamless integration with existing or new third-party systems and eliminating the need for resource-intensive system integration effort.
Sandeep Singh, Senior Vice President and General Manager for Mavenir’s Digital Business Enablement commented: “Mavenir’s Digital BSS is a transformative solution for service providers looking to stay ahead of the competition and launch innovative offerings in a fast time-to-market. Our arrival on AWS Marketplace is a strategic acceleration of our mission to drive sustainable global network automation and monetization, empowering the world’s operators to roll out advanced digital experiences at scale.”
He added: “By facilitating end-to-end digitization of customer interactions and streamlining collaboration with third-party partners – all within a stable and agile architecture – MDE Digital BSS provides service providers with a complete innovation framework to create seamless, personalized network service experiences for customers, and realize the gains with flexible monetization capabilities.”
John Abraham, Principal Analyst, Appledore Research noted: “One of the main innovation barriers for CSPs is the inflexibility of incumbent legacy BSS ecosystems, which require substantial investment in time, cost, and operational resources to enable new revenue models and service capabilities. Simplifying the path to the timely introduction of new business models and innovative best practices, as Mavenir is enabling with its MDE solution, provides CSPs with a distinct advantage in time to market and TCO.”
The MDE platform not only enables greenfield service providers to bring new services to market rapidly but also empowers brownfield service providers to modernize their legacy stack, accelerate digital transformation, and provides a viable path to migrate to 5G while co-existing with existing technologies (2G/3G/4G). MDE brings marketplace capabilities to service providers to cross sell 3rd Party Partner-led product and services integrated with CSPs and Mobile Virtual Network Operators (MVNOs) worldwide. The platform uses advanced AI-ML engines to derive intelligence from customer and network data, which is then used to recommend new products based on historical behavior, and also delivers categorization capabilities that enable service providers to fully capitalize on their rich datasets – bringing new revenues and boosting customer stickiness.
Notes to editors:
- More information about Mavenir’s Digital BSS:
https://www.mavenir.com/portfolio/mavapps/mavenir-digital-enablement-bss/
- Mavenir’s listing on AWS Marketplace:
https://aws.amazon.com/marketplace/pp/prodview-ylbqlsfj3bmay
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416395684/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom